Lexicon Pharmaceuticals, Inc. Share Price Nasdaq
Stocks
US5288721047
Biotechnology & Medical Research
| Market Cap | 91Cr 79Cr 75Cr 68Cr 127.54Cr 8.74TCr 128.17Cr 896.54Cr 346.28Cr 4.45TCr 342.63Cr 335.02Cr 14TCr | P/E 2026 * |
-12.2x | P/E 2027 * | -10.9x |
|---|---|---|---|---|---|
| Enterprise Value | 91Cr 79Cr 75Cr 68Cr 127.54Cr 8.74TCr 128.17Cr 896.54Cr 346.28Cr 4.45TCr 342.63Cr 335.02Cr 14TCr | EV / Sales 2026 * |
24x | EV / Sales 2027 * | 45.8x |
| Free-Float |
98.45% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Lexicon Pharmaceuticals, Inc.
| 1 day | +7.56% |
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Exton
CEO | Chief Executive Officer | 56 | 08/07/2024 |
Scott Coiante
DFI | Director of Finance/CFO | 59 | 02/01/2025 |
Michael Davies
CTO | Chief Tech/Sci/R&D Officer | - | 01/02/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Samuel Barker
CHM | Chairman | 83 | 01/01/2005 |
Ray Debbane
CHM | Chairman | 71 | 27/02/2012 |
| Director/Board Member | 67 | 28/08/2007 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +7.56% | +0.99% | - | - | 91Cr | |
| -0.31% | +3.56% | +46.40% | +100.50% | 7.09TCr | |
| +0.39% | +1.82% | +38.93% | +77.73% | 6.23TCr | |
| -3.21% | -5.72% | -17.12% | +350.96% | 2.71TCr | |
| -2.64% | -0.35% | -2.13% | -15.04% | 2.48TCr | |
| +0.71% | +8.50% | +27.76% | -15.29% | 2.06TCr | |
| -1.26% | -10.61% | +170.72% | +290.48% | 1.55TCr | |
| -0.22% | +1.62% | +44.31% | +167.58% | 1.45TCr | |
| +0.73% | +5.00% | -1.33% | +854.55% | 1.41TCr | |
| -0.54% | -0.30% | +27.33% | +202.19% | 1.23TCr | |
| Average | +0.23% | +1.68% | +37.21% | +223.74% | 2.91TCr | |
| Weighted average by Cap. | -0.50% | +1.39% | +35.79% | +161.34% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.79Cr 3.3Cr 3.12Cr 2.83Cr 5.31Cr 363.77Cr 5.33Cr 37Cr 14Cr 185.03Cr 14Cr 14Cr 595.22Cr | 1.99Cr 1.73Cr 1.64Cr 1.49Cr 2.78Cr 190.89Cr 2.8Cr 20Cr 7.56Cr 97Cr 7.48Cr 7.31Cr 312.35Cr |
| Net income | -7.24Cr -6.31Cr -5.95Cr -5.41Cr -10Cr -694.41Cr -10Cr -71Cr -27Cr -353.21Cr -27Cr -27Cr -1.14TCr | -9.1Cr -7.92Cr -7.48Cr -6.79Cr -13Cr -872Cr -13Cr -89Cr -35Cr -443.54Cr -34Cr -33Cr -1.43TCr |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
